(2018-06-25 | NDAQ:PULM) Pulmatrix Announces Positive Top-Line Results from Parts 1 and 2 of the 3-Part Phase 1/1b Clinical Trial of Pulmazole - an Inhaled Dry-Powder iSPERSE™ Formulation of ...

LEXINGTON, Mass., June 25, 2018 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative i ...

Inhaled Itraconazole Therapies: Biopharmaceutical companies are developing inhalable dry powder formulations of itraconazole to treat Allergic Bronchopulmonary Aspergillosis (ABPA) in asthma patients.

LEXINGTON, Mass., July 17, 2018 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM) announced today that all dosing and follow up visits have been completed for Part 3 of the ongoing first-in-human ...

The technology is a dry powder delivery platform that allows ... a phase 1/1b study of PUR1900 demonstrating an approximately 50-fold higher lung delivery at 1/10th the dosing of oral itraconazole.

October 9, 2009 — Monthly cycle–dependent itraconazole is more effective than classic homeopathy for treating recurrent vulvovaginal candidiasis (RVVC), according to the results of a single ...